A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression

DOI 機関リポジトリ 機関リポジトリ (HANDLE) Web Site PubMed 参考文献21件 オープンアクセス
  • Hamano Yukako
    Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
  • Moriwaki Toshikazu
    Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
  • To Keii
    Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
  • Watahiki Takahisa
    Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
  • Yamada Takeshi
    Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
  • Sakashita Shingo
    Department of Pathology, Faculty of Medicine, University of Tsukuba, Japan
  • Hyodo Ichinosuke
    Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan

この論文をさがす

説明

<p>The standard chemotherapies for neuroendocrine tumors (NETs) are somatostatin analog (SSA) and targeted-agents for NET G1/G2 and platinum-based chemotherapy for neuroendocrine carcinoma (NEC), classified according to the WHO criteria of 2010. We report a case of NET, in which tumors were successfully treated with platinum-containing chemotherapy after remarkable progression with SSA. A 46-year-old man with multiple lymph nodes and liver metastases of unknown primary origin was diagnosed with NET G2 based on the examination of a biopsy specimen. His tumors were stable with SSA for a year, but rapidly became enlarged. A second biopsy revealed NEC. He received cisplatin plus etoposide, and his tumors showed a marked reduction in size. </p>

収録刊行物

  • Internal Medicine

    Internal Medicine 58 (8), 1087-1091, 2019-04-15

    一般社団法人 日本内科学会

参考文献 (21)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ